Research Highlights:

  • The PCORnet Blood Pressure Control Laboratory, a new collaborative partnership, analyzed electronic health record data from nearly 1.5 million patients including almost 6 million ambulatory visits with blood pressure measures.
  • Analysis finds 60% of high blood pressure patients have their blood pressure controlled to less than 140/90 mmHg, with few receiving new medications or dose adjustments after high readings are discovered during clinic visits.

Embargoed until 2 p.m. MT/4 p.m. ET Friday, March 6, 2020 

PHOENIX, March 6, 2020 — Large-scale analysis of electronic health record data from across the country reveals potential opportunities for improvement in how high blood pressure is managed, according to research presented today at the American Heart Association’s Epidemiology and Prevention | Lifestyle and Cardiometabolic Health Scientific Sessions 2020. The EPI Scientific Sessions, March 3-6 in Phoenix, is a premier global exchange of the latest advances in population-based cardiovascular science for researchers and clinicians.

The study, along with a description of the Blood Pressure Control Laboratory (BP Control Lab) platform, is publishing simultaneously in the American Heart Association journal Circulation: Cardiovascular Quality and Outcomes.

Data from nearly 1.5 million eligible patients who completed 5.8 million clinic visits over one year, from 23 electronic health record datasets, found that 60% of patients had blood pressure controlled to below 140/90 mmHg. Readings above that level are considered too high and increase risk for heart attack and stroke.

In addition, only 12% of patients who had a high reading during a clinic visit received an order for a new class of blood pressure-lowering medication. The 2017 American College of Cardiology/American Heart Association Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults recommended adjusting blood pressure medications and/or doses when readings are high. When the best practice was followed, the average reduction in blood pressure was relatively large at 15 mmHg.

The researchers’ analysis also found that only 22% of visits that had a high reading included a second reading to confirm the elevated blood pressure, as recommended by the guidelines.

“Our analysis of real world data from PCORnet indicates marked room for improving blood pressure control and blood pressure medication management for many patients,” said Mark J. Pletcher, M.D., M.P.H., BP Control Lab principal investigator and professor of epidemiology and biostatistics at the University of California, San Francisco.

“We were particularly struck by the low rates of medication intensification when blood pressure is found to be high during a clinic visit – if we can improve medication prescribing rates, our data suggest we could make a big difference in blood pressure control,” said Rhonda M. Cooper- DeHoff, Pharm.D., M.S., lead author of the abstract and associate professor in the College of Pharmacy at the University of Florida in Gainesville, Florida.

The BP Control Lab includes data from 23 health care organizations. The average age of patients in the system was 62 years; 10% were young adults (less than 45 years old); 18% were African American; 52% were female; 28% had diabetes; 15% had heart disease; and 14% had depression.

The BP Control Lab is supported by PCORnet®, the National Patient-Centered Clinical Research Network, which is funded by the Patient-Centered Outcomes Research Institute, and is a collaborative effort and partnership between PCORI, the American Heart Association and the American Medical Association. The BP Control Lab is designed to track blood pressure control metrics nationally, and to support randomized controlled trials that compare effectiveness of different blood pressure control strategies.

Co-authors of the article are Valy Fontil, M.D., M.A.S.; Thomas Carton, Ph.D.; Kathryn M. Shaw, M.P.H.; Myra Smith, M.P.H.; Sujung Choi, Ph.D.; Jonathan Todd, Ph.D.; Alanna M. Chamberlain, Ph.D.; Emily C. O’Brien, Ph.D.; Madelaine Faulkner, M.P.H.; Carlos Maeztu, M.A.; Gregory Wozniak, Ph.D.; Michael Rakotz, M.D.; Christina M. Shay, Ph.D.; and Rhonda M. Cooper-DeHoff, Pharm.D., M.S. An additional author for the abstract is Linda Murakami, R.N., M.H.S.A. Author disclosures are in the article and the abstract.

The PCORnet BP Control Lab is supported by the Patient-Centered Outcomes Research Institute (PCORI), the American Medical Association and the American Heart Association.

Additional Resources:

Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at

About the American Heart Association

The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.orgFacebookTwitter or by calling 1-800-AHA-USA1.   


For Media Inquiries and AHA/ASA Expert Perspective: 214-706-1173

Michelle Kirkwood: 703-457-7838;

For Public Inquiries: 800-AHA-USA1 (242-8721) and